Advertisement

Gastric Cancer

, Volume 22, Issue 3, pp 435–445 | Cite as

Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis

  • Kentaro SuganoEmail author
Original Article

Abstract

Background

Helicobacter pylori (H. pylori) is considered to be the most important risk factor for gastric cancer (GC). The International Agency for Research on Cancer reported that H. pylori eradication could reduce the risk of developing GC. Several clinical studies have investigated this relationship as well; however, their results are inconsistent owing to the varied inclusion criteria. To address the effect of H. pylori eradication on GC incidence, we conducted a comprehensive meta-analysis with several subgroup analyses to resolve these inconsistencies.

Methods

We searched MEDLINE and Ichushi-Web to identify randomized control trial and cohort study articles (English or Japanese) through December 2016. Manual searches were also conducted to identify unlisted references in these databases. Eligible studies reported GC incidence as an outcome, with comparisons between H. pylori eradication and control groups. Subgroup analyses were conducted by country, conditions at baseline, and follow-up periods.

Results

We selected 28 studies among 1583 references in the databases and 4 studies by manual searches. The H. pylori eradication group showed significantly lower risk of GC [odds ratio (OR) 0.46; 95% confidence interval 0.39–0.55]. The subgroup analyses indicated that the beneficial effect of eradication was greater in Japan (OR 0.39; 95% CI 0.31–0.49), particularly among those with benign conditions (OR 0.32; 95% CI 0.19–0.54), although none of them was statistically significant. However, reduction of gastric cancer after eradication was significantly greater (p = 0.01) in the groups with long-term (5 years or longer) follow-up (OR 0.32; 95% CI 0.24–0.43) as compared to those with shorter follow-up (less than 5 years) (OR 0.55; 95% CI 0.41–0.72).

Conclusion

Real world data showed that large-scale eradication therapy has been performed mostly for benign conditions in Japan. Since eradication effects in preventing gastric cancer are conceivably greater there, GC incidence may decline faster in Japan than expected from the previous meta-analyses data which were based on multi-national, mixed populations with differing screening quality and disease progression.

Keywords

Helicobacter pylori eradication Systematic review Meta-analysis Gastric cancer prevention 

Notes

Acknowledgements

The author would like to thank Tomomi Takeshima, PhD, and Wentao Tang, PhD, employees of Milliman, for performing the literature search, developing the first draft (TT) and analyzing data (WT). The author would also like to thank Shinzo Hiroi, PhD, at the time employed by Takeda Pharmaceutical Co., Ltd., for contribution to study design and interpretation of data and to Akihito Uda, Takeda Pharmaceutical Co., Ltd., for coordinating this study. I would like to thank Editage (http://www.editage.jp) for English language editing.

Compliance with ethical standards

Human rights statement

This study is a meta-analysis on the published literatures and does not contain any studies with human or animal subjects.

Informed consent

No individual patient data were used for the analysis, which should exempt this study from the requirement of obtaining informed consents.

Conflict of interest

KS has received research grants from Eisai Pharma, Daiichi Sankyo Pharma, and Takeda Pharmaceutical Co., Ltd, and received lecture fees from Astellas Pharma, Fujifilm, EA Pharma, and Takeda Pharmaceutical Co., Ltd. This study was funded by Takeda Pharmaceutical Co. Ltd.

Supplementary material

10120_2018_876_MOESM1_ESM.pdf (121 kb)
Supplementary material 1 (PDF 121 KB)

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). Lyon, France: International Agency for Research on Cancer. 2013. http://globocan.iarc.fr. Accessed 1 Apr 2018.
  3. 3.
    Cancer Registry and Statistics (Internet). Cancer Information Service, National Cancer Center, Japan. 2014. https://ganjoho.jp/en/professional/statistics/table. Accessed 1 Apr 2018.
  4. 4.
    Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.Google Scholar
  5. 5.
    Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169–79.CrossRefGoogle Scholar
  6. 6.
    Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151:121–8.CrossRefGoogle Scholar
  7. 7.
    Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.CrossRefGoogle Scholar
  8. 8.
    Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19:243–8.CrossRefGoogle Scholar
  9. 9.
    Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One. 2015;10:e0124725.CrossRefGoogle Scholar
  10. 10.
    Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci. 2015;30:749–56.CrossRefGoogle Scholar
  11. 11.
    Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19:166–75.CrossRefGoogle Scholar
  12. 12.
    Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113–24.e5.CrossRefGoogle Scholar
  13. 13.
    Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort Studies. J Natl Cancer Inst 2016.  https://doi.org/10.1093/jnci/djw132.Google Scholar
  14. 14.
    Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30:414–23.Google Scholar
  15. 15.
    Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, et al. Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: a systematic review and meta-analysis comparing risk ratio with risk difference. PLoS One. 2017;12:e0183321.CrossRefGoogle Scholar
  16. 16.
    Cochrane handbook for systematic reviews of interventions. Version 5.1. 0. The Cochrane Collaboration, 2011. 2013.Google Scholar
  17. 17.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.CrossRefGoogle Scholar
  18. 18.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.CrossRefGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefGoogle Scholar
  20. 20.
    Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefGoogle Scholar
  21. 21.
    Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012;61:812–8.CrossRefGoogle Scholar
  22. 22.
    Li WQ, Ma JL, Zhang L, Brown LM, Li JY, Shen L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014.  https://doi.org/10.1093/jnci/dju116.Google Scholar
  23. 23.
    Zhou L, Lin S, Ding S, Huang X, Jin Z, Cui R, et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chin Med J (Engl). 2014;127:1454–8.Google Scholar
  24. 24.
    Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomark Prev. 1997;6:639–42.Google Scholar
  25. 25.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefGoogle Scholar
  26. 26.
    Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007;25:805–12.CrossRefGoogle Scholar
  27. 27.
    Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.CrossRefGoogle Scholar
  28. 28.
    Ogura K, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008;42:279–83.Google Scholar
  29. 29.
    Shiotani A, Uedo N, Iishi H, Yoshiyuki Y, Ishii M, Manabe N, et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion. 2008;78:113–9.CrossRefGoogle Scholar
  30. 30.
    Mabe K, Takahashi M, Oizumi H, Tsukuma H, Shibata A, Fukase K, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol. 2009;15:4290–7.CrossRefGoogle Scholar
  31. 31.
    Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer. 2009;125:2697–703.CrossRefGoogle Scholar
  32. 32.
    Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75:39–46.CrossRefGoogle Scholar
  33. 33.
    Watanabe M, Kato J, Inoue I, Yoshimura N, Yoshida T, Mukoubayashi C, et al. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int J Cancer. 2012;131:2632–42.CrossRefGoogle Scholar
  34. 34.
    Watari J, Moriichi K, Tanabe H, Kashima S, Nomura Y, Fujiya M, et al. Biomarkers predicting development of metachronous gastric cancer after endoscopic resection: an analysis of molecular pathology of Helicobacter pylori eradication. Int J Cancer. 2012;130:2349–58.CrossRefGoogle Scholar
  35. 35.
    Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut. 2013;62:1425–32.CrossRefGoogle Scholar
  36. 36.
    Shichijo S, Hirata Y, Sakitani K, Yamamoto S, Serizawa T, Niikura R, et al. Distribution of intestinal metaplasia as a predictor of gastric cancer development. J Gastroenterol Hepatol. 2015;30:1260–4.CrossRefGoogle Scholar
  37. 37.
    Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol. 2015;50:638–44.CrossRefGoogle Scholar
  38. 38.
    Ami R, Hatta W, Iijima K, Koike T, Ohkata H, Kondo Y, et al. Factors associated with metachronous gastric cancer development after endoscopic submucosal dissection for early gastric cancer. J Clin Gastroenterol. 2017;51:494–9.CrossRefGoogle Scholar
  39. 39.
    Kim N, Park RY, Cho SI, Lim SH, Lee KH, Lee W, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol. 2008;42:448–54.CrossRefGoogle Scholar
  40. 40.
    Han JS, Jang JS, Choi SR, Kwon HC, Kim MC, Jeong JS, et al. A study of metachronous cancer after endoscopic resection of early gastric cancer. Scand J Gastroenterol. 2011;46:1099–104.CrossRefGoogle Scholar
  41. 41.
    Seo JY, Lee DH, Cho Y, Lee DH, Oh HS, Jo HJ, et al. Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer. Hepatogastroenterology. 2013;60:776–80.Google Scholar
  42. 42.
    Bae SE, Jung HY, Kang J, Park YS, Baek S, Jung JH, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014;109:60–7.CrossRefGoogle Scholar
  43. 43.
    Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014;12:793–800e1.CrossRefGoogle Scholar
  44. 44.
    Kim YI, Choi IJ, Kook MC, Cho SJ, Lee JY, Kim CG, et al. The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Helicobacter. 2014;19:194–201.CrossRefGoogle Scholar
  45. 45.
    Kwon YH, Heo J, Lee HS, Cho CM, Jeon SW. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. Aliment Pharmacol Ther. 2014;39:609–18.CrossRefGoogle Scholar
  46. 46.
    Lim JH, Kim SG, Choi J, Im JP, Kim JS, Jung HC. Risk factors for synchronous or metachronous tumor development after endoscopic resection of gastric neoplasms. Gastric Cancer. 2015;18:817–23.CrossRefGoogle Scholar
  47. 47.
    Kim SB, Lee SH, Bae SI, Jeong YH, Sohn SH, Kim KO, et al. Association between Helicobacter pylori status and metachronous gastric cancer after endoscopic resection. World J Gastroenterol. 2016;22:9794–802.CrossRefGoogle Scholar
  48. 48.
    Kato M, Asaka M, Nakamura T, Azuma T, Tomita E, Kamoshida T, et al. Helicobacter pylori eradication prevents the development of gastric cancer—results of a long-term retrospective study in Japan. Aliment Pharmacol Ther. 2006;24:203–6.CrossRefGoogle Scholar
  49. 49.
    Nakagawa S, Asaka M, Kato M, Nakamura T, Kato C, Fujioka T, et al. Helicobacter pylori eradication and metachronous gastric cancer after endoscopic mucosal resection of early gastric cancer. Aliment Pharmacol Ther. 2006;24:214–8.CrossRefGoogle Scholar
  50. 50.
    Kim HJ, Hong SJ, Ko BM, Cho WY, Cho JY, Lee JS, et al. Helicobacter pylori eradication suppresses metachronous gastric cancer and cyclooxygenase-2 expression after endoscopic resection of early gastric cancer. Korean J Helicobacter Up Gastrointest Res. 2011;11:117–23.CrossRefGoogle Scholar
  51. 51.
    Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536–40.CrossRefGoogle Scholar
  52. 52.
    Cancer Registry Annual Report. 2012 Taiwan (in Taiwanese) (Internet) Health Promotion Administration, Ministry of Health and Welfare. 2015. http://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=5190. Accessed 1 Apr 2018.
  53. 53.
    Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676–82.CrossRefGoogle Scholar
  54. 54.
    Cancer Statistics in Japan. 2015 (Internet). Foundation for Promotion of Cancer Research. 2015. http://ganjoho.jp/data/reg_stat/statistics/brochure/2015/cancer_statistics_2015.pdf. Accessed 1 Apr 2018.
  55. 55.
    Kaneko E, Nakamura T, Umeda N, Fujino M, Niwa H. Outcome of gastric carcinoma detected by gastric mass survey in Japan. Gut. 1977;18:626–30.CrossRefGoogle Scholar
  56. 56.
    Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085–95.CrossRefGoogle Scholar
  57. 57.
    Choi JM, Kim SG, Choi J, Park JY, Oh S, et al. Effect of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc. 2018;88:475–85.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  1. 1.Department of MedicineJichi Medical UniversityShimotsukeJapan

Personalised recommendations